Securities code: 688363 securities abbreviation: Bloomage Biotechnology Corporation Limited(688363) Announcement No.: 2022-002 Bloomage Biotechnology Corporation Limited(688363)
Announcement of 2021 annual performance express
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
The main financial data of 2021 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data shall be subject to the 2021 annual report of Bloomage Biotechnology Corporation Limited(688363) (hereinafter referred to as “the company”), which draws the attention of investors to investment risks.
1、 Main financial data and indicators in 2021
Unit: RMB
Increase / decrease range of the project in the same period of last year in the reporting period (%)
Total operating income 4947773755.75 2632733956.17 87.93
Operating profit 905553294.74 757048293.66 19.62
Total profit 890199228.50 758898277.64 17.30
782334573.48 645839219.95 21.13 net profit attributable to the owner of the parent company
Net profit after deducting non recurring profit and loss: 663336045.63 568226011.10 16.74
Basic earnings per share (yuan) 1.63 1.35 20.74
Weighted average return on net assets 14.60 13.46 1.14
Increase / decrease range at the end of the reporting period (%)
Total assets 7510260556.47 5782166564.811 29.89
Owner’s equity attributable to the parent company 5699012395.15 5019756802.12 13.53
Share capital 480000000.00 480000000.00-
11.87 10.46 13.48 net assets per share attributable to the owner of the parent company (yuan)
Note: 1 The Ministry of Finance issued the accounting standards for Business Enterprises No. 21 – leasing (CaiKuai 2018 [35]) in 2018. The company implemented the new leasing standards from January 1, 2021 and adjusted the financial statements at the beginning of the year when it first implemented. The total assets of the company at the end of last year were 5716894300 yuan. The opening balance of this report in the above table is the consolidated statement data adjusted by the company’s first implementation of the new leasing standards in 2021.
2. Except for the total assets shown in note 1, the beginning amount of this report is the same as that at the end of the previous year legally disclosed.
3. The above financial data and indicators are filled in with the data in the consolidated statements, but have not been audited. The final results shall be subject to the company’s 2021 annual report.
2、 Description of operating performance and financial status
（1） Operating conditions, financial conditions and main factors affecting operating performance during the reporting period
1. Operation and financial status during the reporting period
During the reporting period, the company realized an operating revenue of 4947.7738 million yuan, an increase of 87.93% over the same period of last year; The net profit attributable to the owners of the parent company was 782334600 yuan, an increase of 21.13% over the same period of last year; The net profit attributable to the owners of the parent company after deducting non recurring profits and losses was 663.336 million yuan, an increase of 16.74% over the same period of the previous year.
At the end of the reporting period, the total assets were 7510260600 yuan, an increase of 29.89% over the beginning of the period; The owner’s equity attributable to the parent company was 5699.0124 million yuan, an increase of 13.53% over the beginning of the period.
2. Main factors affecting operating performance
During the reporting period, the company steadily promoted the “four-wheel drive” business layout, the raw material business and medical terminal business grew steadily, the functional skin care business continued to maintain rapid growth, and the functional food business got a good start.
While maintaining a high rate of income growth, the company attaches great importance to the basic capacity-building necessary for long-term sustainable growth, including further improving the company’s R & D strength and continuing to significantly increase R & D investment; Forward looking layout of production capacity to reserve space for future sales growth; Continuously improve the brand strength of functional skin care products and build a national brand; Systematically train talents, optimize and upgrade the organizational structure, build industry 4.0 and build a large operation system. Compared with the above strategic investment, the growth rate of the company’s operating revenue in 2021 is higher than that of the operating profit in the same period.
（2） Analysis of reasons for increase and decrease of main indicators
The operating revenue increased by 87.93% year-on-year, mainly due to the sales revenue of functional skin care products increased by about 146.57% year-on-year, and the steady growth of raw material business and medical terminal business year-on-year. In terms of functional skin care products business, the support of scientific and technological power for product power has been further promoted, the ability of product innovation has been continuously demonstrated, and more new products have been launched during the reporting period; The re purchase contribution of old users has increased, and the four brands have formed a large single product matrix; The national brand building has been quite effective, and the brand strength has been significantly improved. The raw material business increased by about 28.62% year-on-year, which was significantly higher than that of last year. The main reason was that while the pharmaceutical grade and cosmetic grade raw materials increased steadily, food grade raw materials and other raw materials increased significantly.
3、 Risk tips
The main financial data of 2021 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The final data shall be subject to the audited 2021 annual report officially disclosed by the company. Please pay attention to the investment risks.
It is hereby announced.
Bloomage Biotechnology Corporation Limited(688363) board of directors February 26, 2022
